Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 47 of 226 for:    Recruiting, Not yet recruiting, Available Studies | Aortic stenosis

Cardiac Magnetic Resonance Imaging Versus Computed Tomography to Guide Transcatheter Aortic Valve Replacement (TAVR-CMR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03831087
Recruitment Status : Recruiting
First Posted : February 5, 2019
Last Update Posted : February 8, 2019
Sponsor:
Collaborators:
Johannes Kepler University of Linz
Klinikum Wels-Grieskirchen
Information provided by (Responsible Party):
Medical University Innsbruck

Brief Summary:
To prove the non-inferiority of TAVR-CMR compared to TAVR-CT to guide TAVR according to clinical efficacy, defined as implantation success based on the VARC-2 criteria.

Condition or disease Intervention/treatment Phase
Aortic Stenosis Diagnostic Test: TAVR-CMR Diagnostic Test: TAVR-CT Not Applicable

Detailed Description:

Study Title: Cardiac Magnetic Resonance Imaging Versus Computed Tomography to Guide Transcatheter Aortic Valve Replacement (TAVR-CMR).

Coordinating Prinicpal Investigator: Prof. Bernhard Metzler, University Clinic of Internal Medicine III, Cardiology and Angiology, Innsbruck Medical University.

Planned Study Period: 2017-2020.

Objective: To investigate, for the first time, the non-inferiority of TAVR-CMR to contrast-enhanced computed tomography (TAVR-CT) regarding efficacy and safety end-points.

Design: Prospective, randomized, open-label, multi-centre trial.

Patients (planned): 250 patients.

Diagnosis / Inclusion Criteria: Symptomatic severe aortic stenosis scheduled for TAVR based on a local heart-team decision.

Methods: Patients will be randomized in a 1:1 fashion to receive a predefined TAVR-CMR protocol or to receive a standard TAVR-CT protocol within two weeks after inclusion.

Main Outcome Measure: Follow-up will be performed at hospital discharge after TAVR and after 6 months. The primary efficacy outcome is device implantation success at discharge. The secondary endpoints are a combined safety endpoint and a combined clinical efficacy endpoint at baseline and at 6 months, as well as a comparison of imaging procedure related variables (see section 5.11.2). Endpoint definitions are based on the updated 2012 VARC-2 consensus document.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 250 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Cardiac Magnetic Resonance Imaging Versus Computed Tomography to Guide Transcatheter Aortic Valve Replacement: A Randomized Multicenter Trial
Actual Study Start Date : October 30, 2017
Estimated Primary Completion Date : June 1, 2020
Estimated Study Completion Date : January 1, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: MRI Scans

Arm Intervention/treatment
TAVR-CMR
All MR examinations will be performed with a 1.5-T clinical MR imaging unit (AVANTO_fit; Siemens, Erlangen, Germany). The MR protocol consists of a Navigator-gated free breathing 3D "whole-heart" coronary magnetic resonance angiography (MRA), axial 2D true fast imaging with steady-state free precession (true-FISP) during free breathing covering whole body trunk and a coronal 3D fast low-angle shot (FLASH) Gd-MRA.
Diagnostic Test: TAVR-CMR
CMR protocol for the exact determination of the aortic valve dimensions, valve size and implantation route.

TAVR-CT
All CT examinations will be performed on a 128-slice dual-source CT and high-pitch factor. Prospective electrocardiographic synchronization will be applied, triggered into the diastolic phase for the heart. An injected bolus of 70 to 110 mL of nonionic iodine contrast agent will be applied with 370 mg/mL iodine concentration, using an automatic injector at a flow rate of 5 mL/s, followed by 40 mL saline solution. Contrast agent volume for each patient will be calculated by scan time and body weight. Patients will be placed supine with arms overhead. The scan length range from supraaortic branches to the groins.
Diagnostic Test: TAVR-CT
CT protocol for the exact determination of the aortic valve dimensions, valve size and implantation route.




Primary Outcome Measures :
  1. The non-inferiority of TAVR-CMR compared to TAVR-CT to guide TAVR according to clinical efficacy, defined as implantation success based on the VARC-2 criteria. [ Time Frame: 6 months ]
    The primary outcome will be a composite clinical efficacy end-point related to implantation success at hospital discharge, based on the VARC-2 criteria: Absence of procedural mortality AND correct positioning of the prosthetic valve AND intended performance of the prosthetic valve (mean aortic valve gradient < 20mmHg and no valve regurgitation > mild)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 99 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Signed informed consent
  2. Severe aortic stenosis according to recent guidelines (aortic valve area ≤ 1.0cm² or aortic valve index ≤ 0.6 cm²/m²) (1)
  3. Typical symptoms of severe aortic stenosis like shortness of breath, angina or syncope
  4. Patient is evaluated for TAVR

Exclusion Criteria:

  1. Contraindications to perform CMR
  2. Contraindications to perform CT
  3. Contraindications for TAVR or reduced life expectancy < 1 year.
  4. Known hypersensitivity to CMR or CT contrast agents
  5. Killip class ≥ 3
  6. Childbearing potential or inability to exclude pregnancy
  7. Inability to understand and follow study-related instructions
  8. Renal insufficiency KDIGO ≥ 4 or severe renal insufficiency requiring renal replacement therapy
  9. Severe hepatic insufficiency (Child-Pugh class B or C)
  10. Post organ transplantation
  11. Participation in another clinical study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03831087


Contacts
Layout table for location contacts
Contact: Bernhard Metzler, Prof. 00435125040 bernhard.metzler@tirol-kliniken.at
Contact: Gert Klug, Assoc.Prof. 00435125040 gert.klug@tirol-kliniken.at

Locations
Layout table for location information
Austria
University Clinic of Internal Medicine III Recruiting
Innsbruck, Tirol, Austria, 6020
Contact: Bernhard Metzler, Prof.    00435040    bernhard.metzler@tirol-kliniken.at   
Contact: Gert Klug    00435040    gert.klug@tirol-kliniken.at   
Sponsors and Collaborators
Medical University Innsbruck
Johannes Kepler University of Linz
Klinikum Wels-Grieskirchen
Investigators
Layout table for investigator information
Principal Investigator: Bernhard Metzler, Prof. Medical University Innsbruck

Layout table for additonal information
Responsible Party: Medical University Innsbruck
ClinicalTrials.gov Identifier: NCT03831087     History of Changes
Other Study ID Numbers: 20171002-1653
First Posted: February 5, 2019    Key Record Dates
Last Update Posted: February 8, 2019
Last Verified: February 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Aortic Valve Stenosis
Heart Valve Diseases
Heart Diseases
Cardiovascular Diseases
Ventricular Outflow Obstruction